MEK inhibitors have traditionally been used in combination with BRAF inhibitors to enhance the blockade of the MAPK kinase growth signaling pathway in B-Raf-proto-oncogene (BRAF) V600E-mutant cancers [31]. This evidence concerns the gene BRAF and cancer.